| Marihuana medicinal: despejando el humo |
Medical marijuana: clearing away the smoke.
Grant I, Atkinson JH, Gouaux B, Wilsey B.
Center for Medicinal Cannabis Research; University of California, San Diego; San Diego, CA, USA.
Open Neurol J. 2012;6:18-25. Epub 2012 May 4.
Abstract
Recent advances in understanding of the mode of action of tetrahydrocannabinol and related cannabinoid in-gredients of marijuana, plus the accumulating anecdotal reports on potential medical benefits have spurred increasing re-search into possible medicinal uses of cannabis. Recent clinical trials with smoked and vaporized marijuana, as well as other botanical extracts indicate the likelihood that the cannabinoids can be useful in the management of neuropathic pain, spasticity due to multiple sclerosis, and possibly other indications. As with all medications, benefits and risks need to be weighed in recommending cannabis to patients. We present an algorithm that may be useful to physicians in determining whether cannabis might be recommended as a treatment in jurisdictions where such use is permitted.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358713/pdf/TONEUJ-6-18.pdf
|
| Efectos adversos de los canabinoides de uso médico: revisión sistemática |
Adverse effects of medical cannabinoids: a systematic review.
Wang T, Collet JP, Shapiro S, Ware MA.
Department of Epidemiology , McGill University, Montréal, Que.
CMAJ. 2008 Jun 17;178(13):1669-78.
Abstract
BACKGROUND:
The therapeutic use of cannabis and cannabis-based medicines raises safety concerns for patients, clinicians, policy-makers, insurers, researchers and regulators. Although the efficacy of cannabinoids is being increasingly demonstrated in randomized controlled trials, most safety information comes from studies of recreational use. METHODS: We performed a systematic review of safety studies of medical cannabinoids published over the past 40 years to create an evidence base for cannabis-related adverse events and to facilitate future cannabis research initiatives. We critically evaluated the quality of published studies with a view to identifying ways to improve future studies. RESULTS: A total of 321 articles were eligible for evaluation. After excluding those that focused on recreational cannabis use, we included 31 studies (23 randomized controlled trials and 8 observational studies) of medical cannabis use in our analysis. In the 23 randomized controlled trials, the median duration of cannabinoid exposure was 2 weeks (range 8 hours to 12 months). A total of 4779 adverse events were reported among participants assigned to the intervention. Most (4615 [96.6%]) were not serious. Of the 164 serious adverse events, the most common was relapse of multiple sclerosis (21 events [12.8%]), vomiting (16 events [9.8%]) and urinary tract infection (15 events [9.1%]). The rate of nonserious adverse events was higher among participants assigned to medical cannabinoids than among controls (rate ratio [RR] 1.86, 95% confidence interval [CI] 1.57-2.21); the rates of serious adverse events did not differ significantly between these 2 groups (RR 1.04, 95% CI 0.78-1.39). Dizziness was the most commonly reported nonserious adverse event (714 events [15.5%]) among people exposed to cannabinoids. INTERPRETATION: Short-term use of existing medical cannabinoids appeared to increase the risk of nonserious adverse events. The risks associated with long-term use were poorly characterized in published clinical trials and observational studies. High-quality trials of long-term exposure are required to further characterize safety issues related to the use of medical cannabinoids.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2413308/?tool
=pubmed
pdf/20080617s00017p1669.pdf
|
| Uso médico de la marihuana y canabinoides sintéticos |
Aquiles J. Roncoroni
Instituto de Investigaciones Médicas Alfredo Lanari, Facultad de Medicina, Universidad de Buenos Aires. e-mail: ajr@movi.com.ar
Medicina (B. Aires) v.63 n.6 Buenos Aires nov./dic. 2003
Mientras la marihuana (MHN) se usó médicamente en EE.UU entre 1842 y 1937 la Marijuana Tax Act aprobada ese año por el poder legislativo de EE.UU, contra la opinión del representante de la Asociación Médica Americana, cambió totalmente la situación. Esta ley fue propuesta por H. Anslinger, director de la oficina federal de narcóticos atribuyéndole provocación de conducta violenta e insanía. Curiosamente el mismo Anslinger en 1967, atribuía a su consumo la conducta «cobarde» de los jóvenes americanos que eludían la convocatoria a luchar en Vietnam.
http://www.scielo.org.ar/pdf/medba/v63n6/v63n6a13.pdf
|
|
No hay comentarios:
Publicar un comentario